Search
Harmony Biosciences Announces Global Strategic Collaboration with Otsuka Pharmaceutical for HBM7020
2025-06-23 /
Read about 0 minute
Author：小编
Harmony Biosciences has forged a global strategic collaboration agreement with Otsuka Pharmaceutical to jointly advance HBM7020, a groundbreaking bispecific T-cell engager designed for the treatment of autoimmune diseases. Under the terms of this agreement, Otsuka Pharmaceutical has secured an exclusive worldwide license, excluding the Greater China region. In return, Harmony Biosciences will receive an initial payment of USD 47 million, with the potential to garner up to USD 623 million through milestone payments and tiered royalties on future net sales.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
